FindTrial
Sign In

Descriptive Analysis of Changes in Hepatitis B Markers in People Living With HIV on Injectable Therapy.

To Switch or Not to Switch to CAB/RPV in PLWH With Past HBV Infection? Risk of HBV Reactivation? A Need for New HBV Markers?

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06421259
Enrollment
15
Registered
2024-05-20
Start date
2024-05-20
Completion date
2026-05-20
Last updated
2024-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B, Hiv Infection

Brief summary

In order to assess the risk of hepatitis B reactivation in people living with HIV and undergoing injection therapy, we propose to carry out a descriptive analysis of the evolution of hepatitis B markers in this population.

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

-HIV infected patients under injectable ART

Exclusion criteria

-Active HBV infection

Design outcomes

Primary

MeasureTime frameDescription
Risk of HBV reactivation under injectable HIV ARTFrom start of injectable HIV treatment to hepatitis B reactivation, assessed up to 24 monthsHBV serology, DNA HBV levels

Countries

France

Contacts

Primary ContactAlissa NAQVI
naqvi.a@chu-nice.fr492035468

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026